MAPT and Alzheimer disease: Mattsson et al. evaluated the performance of 18F-AV1451 PET imaging and CSF tau in different clinical stages of AD and found that 18F-AV1451 exhibited closely to perfect diagnosis in mild and moderate AD (42).